%0 Journal Article
%T STAT3/p53 pathway activation disrupts IFN-¦Â¨Cinduced dormancy in tumor-repopulating cells
%A Bo Huang
%A Bo Zhu
%A Degao Chen
%A F. Xiao-Feng Qin
%A Feiran Cheng
%A Haizeng Zhang
%A Huafeng Zhang
%A Jiadi Lv
%A Jing Xie
%A Jingwei Ma
%A Jinyan Liu
%A Jun Guo
%A Ke Tang
%A Le Zhang
%A Qingzhu Jia
%A Rol Fiskesund
%A Siqi Mo
%A Tianzhen Zhang
%A Wenqian Dong
%A Xiaoyu Liang
%A Xuetao Cao
%A Xun Jin
%A Yabo Zhou
%A Yan Kong
%A Yuying Liu
%A Zhuo-Wei Hu
%J The Journal of Clinical Investigation
%D 2018
%R 10.1172/JCI96329
%X Dynamic interaction with the immune system profoundly regulates tumor cell dormancy. However, it is unclear how immunological cues trigger cancer cell¨Cintrinsic signaling pathways for entering into dormancy. Here, we show that IFN-¦Â treatment induced tumor-repopulating cells (TRC) to enter dormancy through an indolamine 2,3-dioxygenase/kynurenine/aryl hydrocarbon receptor/p27¨Cdependent (IDO/Kyn/AhR/p27-dependent) pathway. Strategies to block this metabolic circuitry did not relieve dormancy, but led to apoptosis of dormant TRCs in murine and human melanoma models. Specifically, blocking AhR redirected IFN-¦Â signaling to STAT3 phosphorylation through both tyrosine and serine sites, which subsequently facilitated STAT3 nuclear translocation and subsequent binding to the p53 promoter in the nucleus. Upregulation of p53 in turn disrupted the pentose phosphate pathway, leading to excessive ROS production and dormant TRC death. Additionally, in melanoma patients, high expression of IFN-¦Â correlated with tumor cell dormancy. Identification of this mechanism for controlling TRC dormancy by IFN-¦Â provides deeper insights into cancer-immune interaction and potential new cancer immunotherapeutic modalities
%U https://www.jci.org/articles/view/96329